Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines

Award Number: R44GM146506
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2023
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines - Project Summary/Abstract Enteral feeding (EF) is an essential medical procedure used to supply nutrients directly to the gastrointestinal (GI) tract of patients who are unable to eat independently. EF formula is often purchased as a ready-to-use liquid that contains carbohydrates, protein, fats, and micronutrients to ensure adequate nutritional benefit for the patient. Ninety three percent of EF formulas are dosed simultaneously with antibiotics. Because of this, >60% of these patients will experience antibiotic-associated diarrhea (AAD). AAD severely decreases nutrient absorption, hydration status, and quality of life substantially for EF patients. There is currently no treatment for AAD, as each antibiotic regimen prescribed to patients differs based on initial health status, and often >30% of AAD patients further develop antibiotic-resistant Clostridium difficile infections after prolonged antibiotic administration. Probiotics offer a potential therapeutic strategy to counteract AAD, as probiotics have been demonstrated to facilitate carbohydrate digestion, restore healthy microflora, and improve intestinal barrier strength and nutrient absorption. Probiotics, however, are highly susceptible to degradation due to shelf storage and upon oral consumption which has yielded conflicting clinical results across multiple trials in the treatment of AAD. Additionally, EF patients are unable to orally ingest capsule based probiotics, which presents an opportunity to generate formulated probiotics that maintain stability and viability in EF formula and upon consumption. To date, addition of probiotics to EF feed involves breaking capsules and adding powder to EF formula, however this method prevents consistent dosing, decreases viability of probiotics via exposure to formula ingredients and gastric acid, and has the potential for pathogen contamination from hospital worker’s hands. Herein, we propose to use VitaKey’s proprietary liquid- and EF-stable probiotic encapsulation platform developed in Phase I and customize it for probiotic strains selected to maximize the potential efficacy in patients with AAD including Bacteroides fragilis, Lactobacillus acidophilus, and Lactobacillus plantarum. We aim to establish mechanistic support for stabilized probiotics by evaluating treatment in a mouse AAD model followed by further development of formulations capable of: (1) withstanding pasteurization during product manufacturing, (2) attaining long-term shelf-stability, (3) reaching clinically-relevant efficacy levels in a murine model of AAD and (4) scalable manufacturing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	VITAKEY INC	1222 16TH ST NW	WASHINGTON	DC	20036	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	2	12/1/2025	COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,437,278 )
2025	2025	VITAKEY INC	1222 16TH ST NW	WASHINGTON	DC	20036	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	2	8/29/2025	COMPETING CONTINUATION	$1,437,278
2025	2025	VITAKEY INC	1222 16TH ST NW	WASHINGTON	DC	20036	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	001	2	9/8/2025	COMPETING CONTINUATION	$0
														Subtotal = $1,437,278

Grand Total All Awards = $1,437,278

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines

Award Number: R44GM146506

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2023

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer